Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Advertisement

Advertisement




Dec
03
Today In Oncology
Lung Cancer Deaths Prevented and Life-Years Gained From Lung Cancer Screening
Nivolumab and Ipilimumab in Advanced dMMR/MSI-H Noncolorectal Cancers
AYA Cancers Survival for Metastatic Recurrence Worse Than De Novo Metastatic Disease
Survey Finds Global Embrace of Integrative Cancer Care
Addition of Neoadjuvant LuPSMA PNT2002 to SBRT in Oligorecurrent Prostate Cancer
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo